An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.
Journal article
Dold C. et al, (2023), Sci Transl Med, 15
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect, 86, 574 - 583
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
Regulatory T cell profiles in patients with N-methyl-ᴅ-aspartate receptor-antibody encephalitis.
Journal article
Iro MA. et al, (2023), Encephalitis, 3, 15 - 23
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
Journal article
Rollier CS. et al, (2022), Vaccine, 40, 4453 - 4463
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Journal article
Marchevsky NG. et al, (2022), EBioMedicine, 81
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Divergent trajectories of antiviral memory after SARS-CoV-2 infection.
Journal article
Tomic A. et al, (2022), Nat Commun, 13
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.
Journal article
Versteegen P. et al, (2022), Front Immunol, 13
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Journal article
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Journal article
Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
Divergent trajectories of antiviral memory after SARS-Cov-2 infection
Preprint
Tomic* A. et al, (2021)
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nat Med, 27
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Ewer KJ. et al, (2021), Nat Med, 27
Antibody evasion by the P.1 strain of SARS-CoV-2.
Journal article
Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9